PCV123 - ECONOMIC EVALUATION FOR ROSUVASTATIN VS. ATORVASTATIN IN EGYPTIAN PATIENTS WITH HYPERLIPIDEMIA EGYPT CASE

Abstract

According to WHO report (2014) cardiovascular disease (CVD) mortality accounts for 46% of total deaths, all ages and both sexes and high serum cholesterol level representing third risk factors for (CVD) and with high population for country like Egypt with scarcity of resources health care policy maker is looking for efficient managing of resources and enhancement for patients outcomes to achieve that goals selection of efficient treatment polices and formularies play a major role to achieve that goal . The main objective behind conducting this study was to evaluate the cost effectiveness of Rosuvastatin in patients with hyperlipidemia versus atorvastatin, in the Egyptian patients, over a life-time horizon. Model overview The study adopted a two-part cost-utility model comprising a short-term decision tree (one year) and a long-term Markov structure was utilized to estimate long-term costs and health outcomes. The aim of the modeling exercise was to adhere closely to the real practice of hyperlipidemia and the CVD events. The outcome of the two treatment arms was measured by quality-adjusted life years (QALYs). During the life-time horizon, total QALY gained for Rosuvastatin was (3762.70) QALY VS (3676.25) QALY for Atorvastatin with difference 86.46 QALY with expected saving of treatment budget with 12 %. Using Rosuvastatin as treatment priority for patients with hyperlipidemia patients may enhance patient’s outcomes and saving for resources.